迪哲医药(688192) - 2023 Q3 - 季度财报

Financial Performance - The total operating revenue for the third quarter of 2023 was CNY 40,102,400, with a net profit attributable to shareholders of CNY -314,696,989.70[14] - Total operating revenue for the first three quarters of 2023 reached ¥40,102,400, compared to no revenue reported in the same period of 2022[28] - Net loss for the third quarter of 2023 was ¥828,949,591.21, compared to a net loss of ¥510,097,218.65 in the same quarter of 2022, indicating a worsening of approximately 62.5%[29] - The company's net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -320,083,888.33 for the quarter[14] - Basic and diluted earnings per share for the third quarter of 2023 were both reported at -¥2.03, compared to -¥1.26 in the same quarter of 2022[35] - The company incurred a basic and diluted earnings per share of -0.77 RMB for the current period[54] Research and Development - Research and development expenses increased to CNY 55.90 million during the reporting period, reflecting progress in ongoing product development[6] - Research and development expenses for the first three quarters of 2023 amounted to ¥578,964,914.76, up from ¥480,663,642.45 in 2022, reflecting a year-over-year increase of about 20.5%[28] - The company reported a total research and development expenditure of 235,527,010.26 RMB, which is 587.31% of its operating revenue[54] - The company is advancing its blood cancer product, Golisicitinib, which has received priority review status from the National Medical Products Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma[18] - The company received approval from the National Medical Products Administration for its lung cancer targeted drug, Shuwotai (generic name: Shuwotai), for specific treatment indications[59] Assets and Liabilities - The company reported a total asset value of CNY 1,673,342,924.00, down from CNY 2,081,908,055.24 at the end of the previous year[19] - The company's total assets decreased to ¥1,673,342,924.00 as of September 30, 2023, down from ¥2,081,908,055.24 at the end of 2022, a reduction of approximately 19.6%[24] - The company’s equity attributable to shareholders decreased to CNY -38.45 million, indicating a continued loss status compared to the end of last year[6] - The equity attributable to shareholders of the listed company is 1,082,273,585.39 RMB, down 38.45% from the previous year[54] - The company’s total liabilities included short-term borrowings of CNY 199,920,121.95, indicating increased leverage[19] - Total liabilities increased significantly to ¥591,069,338.61 in 2023 from ¥323,427,016.13 in 2022, marking an increase of about 83%[24] - The company's retained earnings showed a significant deficit of ¥2,234,801,204.92 as of September 30, 2023, compared to a deficit of ¥1,405,851,613.71 at the end of 2022[24] Cash Flow - The company’s cash and cash equivalents decreased from CNY 1,473,178,113.01 to CNY 1,084,851,232.36, indicating a liquidity contraction[19] - Cash and cash equivalents decreased to ¥69,398,112.49 as of September 30, 2023, down from ¥121,674,499.67 at the end of 2022, a decline of approximately 43%[22] - The net cash flow from operating activities for the current period is -669,132,575.97 RMB, compared to -421,450,780.29 RMB in the previous period, indicating a significant increase in cash outflow[38] - The total cash inflow from investment activities is 3,468,191,094.88 RMB, while cash outflow is 3,025,188,087.27 RMB, resulting in a net cash flow from investment activities of 443,003,007.61 RMB[38] - The net cash flow from financing activities is 175,902,153.78 RMB, compared to -31,391,757.15 RMB in the previous period, showing a positive shift in financing[40] New Products and Market Activity - The company has launched a new product, Shuwozhe®, in August 2023, which has started generating sales revenue[50] - The company reported a fair value change gain of ¥18,310,623.89 in the first three quarters of 2023, down from ¥33,183,648.81 in the same period of 2022[29] - The company reported a non-monetary asset exchange gain of approximately 5.25 million and a fair value change gain of about 18.31 million, primarily from financial investment returns[55] - The total number of common shareholders at the end of the reporting period was 9,884, with the top ten shareholders holding significant stakes[69]